NCT06699420RecruitingPhase 4
Qishenyiqi Dripping Pill for Coronary Microvascular Disease
The Efficacy and Safety of Qishenyiqi Dripping Pill in Patients With Coronary Microvascular Disease
Source: ClinicalTrials.gov · Last updated 21 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- First submitted
- 18 Nov 2024
- Start date
- 8 Nov 2023
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Coronary artery disease
- NCT number
- NCT06699420
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 162
- From 8 Nov 2023 to the primary completion date, 31 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous myocardial infarction or PCI or CABG treatment;
- Patients who participated in clinical research of other drugs within 3 months before being selected.
Other illness
- A history of heart failure;
- Severe arrhythmia;
- Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm;
- Takayasu arteritis, Kawasaki disease or coronary artery malformation;
- Allergic to contrast agents or traditional Chinese medicines;
Other
- Familial hypercholesterolemia;
- Pregnant or nursing, or having the intention to give birth within one year;
- Hepatic or renal dysfunction;
Who the study is looking for
- Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;
- Coronary normal or stenosis \< 20%;
- Ischemic depression in ST segment during resting or exercise;
- Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0;
- Subjects or their guardians agreed to participate in this study.
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qilu Hospital of Shandong University Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
| Qianfoshan Hospital, Shandong University Coordinator of this site? Confirm its status | Jinan | China | Active, not recruiting |
| Jinan Central Hospital Affiliated to Shandong First Medical University Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.